Inaqovi 35 mg/100 mg film coated tablets
*Company:
Otsuka Pharmaceutical UK Ltd.Status:
UpdatedLegal Category:
Product subject to restricted prescription (C)Active Ingredient(s):
This medicinal product is subject to additional monitoring.
*Additional information is available within the SPC or upon request to the company
Updated on 29 June 2026
File name
Inaqovi SmPC IE - Clean - Extension of indication.pdf
Reasons for updating
- Change to section 4.1 - Therapeutic indications
- Change to section 4.2 - Posology and method of administration
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 6.5 - Nature and contents of container
- Change to section 10 - Date of revision of the text
Legal category:Product subject to restricted prescription (C)
Updated on 29 June 2026
File name
Inaqovi PIL IE - Clean - Extension of indication.pdf
Reasons for updating
- Change to section 1 - what the product is used for
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 3 - dose and frequency
- Change to MA holder contact details
Updated on 24 March 2025
File name
Inaqovi PIL IE.pdf
Reasons for updating
- Change to MA holder contact details
Updated on 24 March 2025
File name
Inaqovi SmPC IE.pdf
Reasons for updating
- Change to section 6.3 - Shelf life
Legal category:Product subject to restricted prescription (C)
Updated on 28 January 2025
File name
Inaqovi_PIL_Ireland.pdf
Reasons for updating
- Change to section 6 - manufacturer
Updated on 13 February 2024
File name
Inaqovi_PIL_Ireland.pdf
Reasons for updating
- Change to section 6 - manufacturer
Free text change information supplied by the pharmaceutical company
Addition of R-Pharm as Batch Release Site
Updated on 19 October 2023
File name
Inaqovi_SmPC_Ireland.pdf
Reasons for updating
- New SPC for new product
Legal category:Product subject to restricted prescription (C)
Free text change information supplied by the pharmaceutical company
New SmPC for new product
Updated on 19 October 2023
File name
Inaqovi_SmPC_Ireland.pdf
Reasons for updating
- New SPC for new product
Legal category:Product subject to restricted prescription (C)
Free text change information supplied by the pharmaceutical company
New SmPC for new product
Updated on 19 October 2023
File name
Inaqovi_PIL_Ireland.pdf
Reasons for updating
- New PIL for new product
Free text change information supplied by the pharmaceutical company
New PIL for new product
Updated on 19 October 2023
File name
Inaqovi_PIL_Ireland.pdf
Reasons for updating
- New PIL for new product
Free text change information supplied by the pharmaceutical company
New product PIL
Otsuka Pharmaceutical UK Ltd.
Address:
Otsuka Pharmaceuticals (U.K.) Ltd., 2 Windsor Dials, Arthur Road, Windsor SL4 1RS, United KingdomMedical Information E-mail:
medical.information@otsuka-europe.comTelephone:
44 (0)203 747 5300Stock Availability:
n/a